Skip to main content
Equibles
KROS logo

KROS · Keros Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track KROS — free

Use KROS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KROS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.08 +0.54 (+5.66%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$197.81M
Shares
19.62M
Volume · Nov 12 630.16K Avg daily vol (3M) 187.94K

Keros Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Keros Therapeutics, Inc. (KROS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)

Embed Keros Therapeutics, Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview
                
            

        

        
    

    




    
    
    


        

    

        

            

                Key facts
                    
                        CIK
                        1664710
                    
                    
                        CUSIP
                        492327101
                    
                    
                        13F (30d)
                        85 filings
                        70 filers
                    
                    
                    
                         Visit website
                        
                    
                    
                         Investor relations